Achilles Therapeutics PLC (STU:698)
€ 0.955 -0.005 (-0.52%) Market Cap: 39.24 Mil Enterprise Value: -45.30 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 40/100

Achilles Therapeutics PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript

Apr 24, 2023 / 03:30PM GMT
Geulah Livshits
Chardan - Analyst

Hello. It's now my pleasure to introduce Dr. Iraj Ali, CEO; and Dr. Ed Samuel, EVP, Technical Operations of Achilles Therapeutics. This fireside chat will be around 25 minutes. And the audience can ask questions during the session by entering them into the question box below.

Questions & Answers

Geulah Livshits
Chardan - Analyst

So to start off, thank you both for joining us today. Can you give us a brief overview of Achilles [PELEUS] platform and its manufacturing process?

Iraj Ali
Achilles Therapeutics plc - CEO

Sure. Thanks for the invitation to talk and tell you a little bit more about Achilles. So maybe we'll just advance to the forward-looking statements. And I'd encourage people to review those in their own time. It's available on our presentation attached on our website.

But maybe if we move into the overview of Achilles, particularly for those who may be new to the story. We are targeting clonal neoantigens with patented technology and think that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot